$MPLT News
Last published 11h ago
- 11h agoMPLTMapLight Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 11h agoMPLTMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePlanning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028
- 1w agoMPLTMapLight Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswireSAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conference: Event:
- 2mo agoMPLTMapLight Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conference: Event:
- 3mo agoMPLTMapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireReported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with
- 3mo agoMPLTMapLight Therapeutics Announces $150 Million Private Placement FinancingGlobeNewswireSAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating
- 3mo agoMPLTTopline Results from the Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - MAPLIGHT THERAPEUTICS INCEarnings Call TranscriptsGood day, and welcome to the top-line results from the Phase 2 Zephyr Study of ML007C, MA and Schizophrenia. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a quest
- 3mo agoMPLTMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in SchizophreniaGlobeNewswireThe trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with
- 4mo agoMPLTMapLight Therapeutics Announces Changes to Board of DirectorsGlobeNewswireSAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating
- 4mo agoMPLTTopline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder - MAPLIGHT THERAPEUTICS INCEarnings Call TranscriptsGood day and welcome to the top line results from Phase 2 of our study for ML004 and Autism Spectrum Disorder. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a que
- 4mo agoMPLTMapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum DisorderGlobeNewswireThe IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-I ≥ 16)
- 6mo agoMPLTMapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireEnrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004's Phase 2 IRIS trial in autism spectrum disorder, with
- 6mo agoMPLTMapLight Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event:
- 6mo agoMPLTMapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline ResultsGlobeNewswireEnrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by
- 7mo agoMPLTMapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePhase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum
- 8mo agoMPLTMapLight Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event:
- 10mo agoMPLTMapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026GlobeNewswireSAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (NASDAQ:MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and
- 10mo agoMPLTMapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease PsychosisGlobeNewswireSAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. ("MapLight") (NASDAQ:MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
- 11mo agoMPLTSandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS TherapiesGlobeNewswireSAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (NASDAQ:MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop
- 11mo agoMPLTMapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate ProgressGlobeNewswireTopline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second
- 1y agoMPLTMapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous
- 1y agoMPLTMapLight Therapeutics Announces Pricing of Initial Public OfferingGlobeNewswireSAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous